BIO
Bio-Rad Laboratories, Inc.
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
In a year already marked by headlines of Ebola outbreaks and flashback-inducing cruise ship quarantines, everyday foodborne threats are delivering a sharp reminder of supply chain vulnerability. Since
VANCOUVER, BC, Canada – TheNewswire - July 17, 2026 — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) (“Noveris” or the “Company”) is pleased to announce that it has joined the Biote
BIO-key (BKYI) a global leader in biometric-powered identity & access management to participate at Jordan Banking Cybersecurity Workshop in Amman, July 6.
I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting